世界の心筋線維症市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Myocardial Fibrosis Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-4542 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、108ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、心筋線維症の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（小分子治療法、タンパク質治療法、ペプチド治療法、エンドグリン抗体療法法、幹細胞治療法、RNA治療法、その他）、用途別市場規模（病院、クリニック、研究所）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・心筋線維症の市場動向 ・企業の競争状況、市場シェア ・心筋線維症の種類別市場規模と予測2016-2027（小分子治療法、タンパク質治療法、ペプチド治療法、エンドグリン抗体療法法、幹細胞治療法、RNA治療法、その他） ・心筋線維症の用途別市場規模と予測2016-2027（病院、クリニック、研究所） ・心筋線維症の北米市場規模2016-2027（アメリカ、カナダ） ・心筋線維症の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・心筋線維症のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・心筋線維症の中南米市場規模2016-2027（メキシコ、ブラジル） ・心筋線維症の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Merck、Evotec AG、Miragen Therapeutics、TRACON Pharmaceuticals、Daewoong Pharmaceutical、Galectin Therapeutics、GTx、Invivosciences、Lead Discovery Center、MandalMed） ・結論

Myocardial fibrosis is an abnormal thickening of the heart valves due to inappropriate proliferation of cardiac fibroblasts. Symptoms include chest pain, some abdominal swelling,nausea and fatigue.Myocardial fibrosis, also known as myocardial calcification, is the result of sustained myocardial fiber and/or repeated aggravation of myocardial ischemia and hypoxia caused by moderate to severe coronary atherosclerotic stenosis, leading to the progressive development of heart failure with IHD, or chronic ischemic heart disease

Market Analysis and Insights: Global Myocardial Fibrosis Market
The global Myocardial Fibrosis market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Myocardial Fibrosis market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Myocardial Fibrosis market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Myocardial Fibrosis market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Myocardial Fibrosis market.

Global Myocardial Fibrosis Scope and Market Size
Myocardial Fibrosis market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Myocardial Fibrosis market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Small Molecule Therapeutic Modality
Protein Therapeutic Modality
Peptide Therapeutic Modality
Endoglin Antibody Therapeutic Modality
Stem Cell Therapeutic Modality
RNA Therapeutic Modality
Other

Segment by Application
Hospital
Clinics
Research Laboratories

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Merck
Evotec AG
Miragen Therapeutics
TRACON Pharmaceuticals
Daewoong Pharmaceutical
Galectin Therapeutics
GTx
Invivosciences
Lead Discovery Center
MandalMed

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Myocardial Fibrosis Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Small Molecule Therapeutic Modality
1.2.3 Protein Therapeutic Modality
1.2.4 Peptide Therapeutic Modality
1.2.5 Endoglin Antibody Therapeutic Modality
1.2.6 Stem Cell Therapeutic Modality
1.2.7 RNA Therapeutic Modality
1.2.8 Other
1.3 Market by Application
1.3.1 Global Myocardial Fibrosis Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Research Laboratories
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Myocardial Fibrosis Market Perspective (2016-2027)
2.2 Myocardial Fibrosis Growth Trends by Regions
2.2.1 Myocardial Fibrosis Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Myocardial Fibrosis Historic Market Share by Regions (2016-2021)
2.2.3 Myocardial Fibrosis Forecasted Market Size by Regions (2022-2027)
2.3 Myocardial Fibrosis Industry Dynamic
2.3.1 Myocardial Fibrosis Market Trends
2.3.2 Myocardial Fibrosis Market Drivers
2.3.3 Myocardial Fibrosis Market Challenges
2.3.4 Myocardial Fibrosis Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Myocardial Fibrosis Players by Revenue
3.1.1 Global Top Myocardial Fibrosis Players by Revenue (2016-2021)
3.1.2 Global Myocardial Fibrosis Revenue Market Share by Players (2016-2021)
3.2 Global Myocardial Fibrosis Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Myocardial Fibrosis Revenue
3.4 Global Myocardial Fibrosis Market Concentration Ratio
3.4.1 Global Myocardial Fibrosis Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Myocardial Fibrosis Revenue in 2020
3.5 Myocardial Fibrosis Key Players Head office and Area Served
3.6 Key Players Myocardial Fibrosis Product Solution and Service
3.7 Date of Enter into Myocardial Fibrosis Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Myocardial Fibrosis Breakdown Data by Type
4.1 Global Myocardial Fibrosis Historic Market Size by Type (2016-2021)
4.2 Global Myocardial Fibrosis Forecasted Market Size by Type (2022-2027)

5 Myocardial Fibrosis Breakdown Data by Application
5.1 Global Myocardial Fibrosis Historic Market Size by Application (2016-2021)
5.2 Global Myocardial Fibrosis Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Myocardial Fibrosis Market Size (2016-2027)
6.2 North America Myocardial Fibrosis Market Size by Type
6.2.1 North America Myocardial Fibrosis Market Size by Type (2016-2021)
6.2.2 North America Myocardial Fibrosis Market Size by Type (2022-2027)
6.2.3 North America Myocardial Fibrosis Market Size by Type (2016-2027)
6.3 North America Myocardial Fibrosis Market Size by Application
6.3.1 North America Myocardial Fibrosis Market Size by Application (2016-2021)
6.3.2 North America Myocardial Fibrosis Market Size by Application (2022-2027)
6.3.3 North America Myocardial Fibrosis Market Size by Application (2016-2027)
6.4 North America Myocardial Fibrosis Market Size by Country
6.4.1 North America Myocardial Fibrosis Market Size by Country (2016-2021)
6.4.2 North America Myocardial Fibrosis Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Myocardial Fibrosis Market Size (2016-2027)
7.2 Europe Myocardial Fibrosis Market Size by Type
7.2.1 Europe Myocardial Fibrosis Market Size by Type (2016-2021)
7.2.2 Europe Myocardial Fibrosis Market Size by Type (2022-2027)
7.2.3 Europe Myocardial Fibrosis Market Size by Type (2016-2027)
7.3 Europe Myocardial Fibrosis Market Size by Application
7.3.1 Europe Myocardial Fibrosis Market Size by Application (2016-2021)
7.3.2 Europe Myocardial Fibrosis Market Size by Application (2022-2027)
7.3.3 Europe Myocardial Fibrosis Market Size by Application (2016-2027)
7.4 Europe Myocardial Fibrosis Market Size by Country
7.4.1 Europe Myocardial Fibrosis Market Size by Country (2016-2021)
7.4.2 Europe Myocardial Fibrosis Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Myocardial Fibrosis Market Size (2016-2027)
8.2 Asia-Pacific Myocardial Fibrosis Market Size by Type
8.2.1 Asia-Pacific Myocardial Fibrosis Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Myocardial Fibrosis Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Myocardial Fibrosis Market Size by Type (2016-2027)
8.3 Asia-Pacific Myocardial Fibrosis Market Size by Application
8.3.1 Asia-Pacific Myocardial Fibrosis Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Myocardial Fibrosis Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Myocardial Fibrosis Market Size by Application (2016-2027)
8.4 Asia-Pacific Myocardial Fibrosis Market Size by Region
8.4.1 Asia-Pacific Myocardial Fibrosis Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Myocardial Fibrosis Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Myocardial Fibrosis Market Size (2016-2027)
9.2 Latin America Myocardial Fibrosis Market Size by Type
9.2.1 Latin America Myocardial Fibrosis Market Size by Type (2016-2021)
9.2.2 Latin America Myocardial Fibrosis Market Size by Type (2022-2027)
9.2.3 Latin America Myocardial Fibrosis Market Size by Type (2016-2027)
9.3 Latin America Myocardial Fibrosis Market Size by Application
9.3.1 Latin America Myocardial Fibrosis Market Size by Application (2016-2021)
9.3.2 Latin America Myocardial Fibrosis Market Size by Application (2022-2027)
9.3.3 Latin America Myocardial Fibrosis Market Size by Application (2016-2027)
9.4 Latin America Myocardial Fibrosis Market Size by Country
9.4.1 Latin America Myocardial Fibrosis Market Size by Country (2016-2021)
9.4.2 Latin America Myocardial Fibrosis Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Myocardial Fibrosis Market Size (2016-2027)
10.2 Middle East & Africa Myocardial Fibrosis Market Size by Type
10.2.1 Middle East & Africa Myocardial Fibrosis Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Myocardial Fibrosis Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Myocardial Fibrosis Market Size by Type (2016-2027)
10.3 Middle East & Africa Myocardial Fibrosis Market Size by Application
10.3.1 Middle East & Africa Myocardial Fibrosis Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Myocardial Fibrosis Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Myocardial Fibrosis Market Size by Application (2016-2027)
10.4 Middle East & Africa Myocardial Fibrosis Market Size by Country
10.4.1 Middle East & Africa Myocardial Fibrosis Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Myocardial Fibrosis Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Merck
11.1.1 Merck Company Details
11.1.2 Merck Business Overview
11.1.3 Merck Myocardial Fibrosis Introduction
11.1.4 Merck Revenue in Myocardial Fibrosis Business (2016-2021)
11.1.5 Merck Recent Development
11.2 Evotec AG
11.2.1 Evotec AG Company Details
11.2.2 Evotec AG Business Overview
11.2.3 Evotec AG Myocardial Fibrosis Introduction
11.2.4 Evotec AG Revenue in Myocardial Fibrosis Business (2016-2021)
11.2.5 Evotec AG Recent Development
11.3 Miragen Therapeutics
11.3.1 Miragen Therapeutics Company Details
11.3.2 Miragen Therapeutics Business Overview
11.3.3 Miragen Therapeutics Myocardial Fibrosis Introduction
11.3.4 Miragen Therapeutics Revenue in Myocardial Fibrosis Business (2016-2021)
11.3.5 Miragen Therapeutics Recent Development
11.4 TRACON Pharmaceuticals
11.4.1 TRACON Pharmaceuticals Company Details
11.4.2 TRACON Pharmaceuticals Business Overview
11.4.3 TRACON Pharmaceuticals Myocardial Fibrosis Introduction
11.4.4 TRACON Pharmaceuticals Revenue in Myocardial Fibrosis Business (2016-2021)
11.4.5 TRACON Pharmaceuticals Recent Development
11.5 Daewoong Pharmaceutical
11.5.1 Daewoong Pharmaceutical Company Details
11.5.2 Daewoong Pharmaceutical Business Overview
11.5.3 Daewoong Pharmaceutical Myocardial Fibrosis Introduction
11.5.4 Daewoong Pharmaceutical Revenue in Myocardial Fibrosis Business (2016-2021)
11.5.5 Daewoong Pharmaceutical Recent Development
11.6 Galectin Therapeutics
11.6.1 Galectin Therapeutics Company Details
11.6.2 Galectin Therapeutics Business Overview
11.6.3 Galectin Therapeutics Myocardial Fibrosis Introduction
11.6.4 Galectin Therapeutics Revenue in Myocardial Fibrosis Business (2016-2021)
11.6.5 Galectin Therapeutics Recent Development
11.7 GTx
11.7.1 GTx Company Details
11.7.2 GTx Business Overview
11.7.3 GTx Myocardial Fibrosis Introduction
11.7.4 GTx Revenue in Myocardial Fibrosis Business (2016-2021)
11.7.5 GTx Recent Development
11.8 Invivosciences
11.8.1 Invivosciences Company Details
11.8.2 Invivosciences Business Overview
11.8.3 Invivosciences Myocardial Fibrosis Introduction
11.8.4 Invivosciences Revenue in Myocardial Fibrosis Business (2016-2021)
11.8.5 Invivosciences Recent Development
11.9 Lead Discovery Center
11.9.1 Lead Discovery Center Company Details
11.9.2 Lead Discovery Center Business Overview
11.9.3 Lead Discovery Center Myocardial Fibrosis Introduction
11.9.4 Lead Discovery Center Revenue in Myocardial Fibrosis Business (2016-2021)
11.9.5 Lead Discovery Center Recent Development
11.10 MandalMed
11.10.1 MandalMed Company Details
11.10.2 MandalMed Business Overview
11.10.3 MandalMed Myocardial Fibrosis Introduction
11.10.4 MandalMed Revenue in Myocardial Fibrosis Business (2016-2021)
11.10.5 MandalMed Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Myocardial Fibrosis Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Small Molecule Therapeutic Modality
Table 3. Key Players of Protein Therapeutic Modality
Table 4. Key Players of Peptide Therapeutic Modality
Table 5. Key Players of Endoglin Antibody Therapeutic Modality
Table 6. Key Players of Stem Cell Therapeutic Modality
Table 7. Key Players of RNA Therapeutic Modality
Table 8. Key Players of Other
Table 9. Global Myocardial Fibrosis Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 10. Global Myocardial Fibrosis Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 11. Global Myocardial Fibrosis Market Size by Regions (2016-2021) & (US$ Million)
Table 12. Global Myocardial Fibrosis Market Share by Regions (2016-2021)
Table 13. Global Myocardial Fibrosis Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 14. Global Myocardial Fibrosis Market Share by Regions (2022-2027)
Table 15. Myocardial Fibrosis Market Trends
Table 16. Myocardial Fibrosis Market Drivers
Table 17. Myocardial Fibrosis Market Challenges
Table 18. Myocardial Fibrosis Market Restraints
Table 19. Global Myocardial Fibrosis Revenue by Players (2016-2021) & (US$ Million)
Table 20. Global Myocardial Fibrosis Market Share by Players (2016-2021)
Table 21. Global Top Myocardial Fibrosis Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Myocardial Fibrosis as of 2020)
Table 22. Ranking of Global Top Myocardial Fibrosis Companies by Revenue (US$ Million) in 2020
Table 23. Global 5 Largest Players Market Share by Myocardial Fibrosis Revenue (CR5 and HHI) & (2016-2021)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Myocardial Fibrosis Product Solution and Service
Table 26. Date of Enter into Myocardial Fibrosis Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Myocardial Fibrosis Market Size by Type (2016-2021) (US$ Million)
Table 29. Global Myocardial Fibrosis Revenue Market Share by Type (2016-2021)
Table 30. Global Myocardial Fibrosis Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 31. Global Myocardial Fibrosis Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 32. Global Myocardial Fibrosis Market Size Share by Application (2016-2021) & (US$ Million)
Table 33. Global Myocardial Fibrosis Revenue Market Share by Application (2016-2021)
Table 34. Global Myocardial Fibrosis Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 35. Global Myocardial Fibrosis Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 36. North America Myocardial Fibrosis Market Size by Type (2016-2021) (US$ Million)
Table 37. North America Myocardial Fibrosis Market Size by Type (2022-2027) & (US$ Million)
Table 38. North America Myocardial Fibrosis Market Size by Application (2016-2021) (US$ Million)
Table 39. North America Myocardial Fibrosis Market Size by Application (2022-2027) & (US$ Million)
Table 40. North America Myocardial Fibrosis Market Size by Country (2016-2021) & (US$ Million)
Table 41. North America Myocardial Fibrosis Market Size by Country (2022-2027) & (US$ Million)
Table 42. Europe Myocardial Fibrosis Market Size by Type (2016-2021) (US$ Million)
Table 43. Europe Myocardial Fibrosis Market Size by Type (2022-2027) & (US$ Million)
Table 44. Europe Myocardial Fibrosis Market Size by Application (2016-2021) (US$ Million)
Table 45. Europe Myocardial Fibrosis Market Size by Application (2022-2027) & (US$ Million)
Table 46. Europe Myocardial Fibrosis Market Size by Country (2016-2021) & (US$ Million)
Table 47. Europe Myocardial Fibrosis Market Size by Country (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Myocardial Fibrosis Market Size by Type (2016-2021) (US$ Million)
Table 49. Asia-Pacific Myocardial Fibrosis Market Size by Type (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Myocardial Fibrosis Market Size by Application (2016-2021) (US$ Million)
Table 51. Asia-Pacific Myocardial Fibrosis Market Size by Application (2022-2027) & (US$ Million)
Table 52. Asia-Pacific Myocardial Fibrosis Market Size by Region (2016-2021) & (US$ Million)
Table 53. Asia-Pacific Myocardial Fibrosis Market Size by Region (2022-2027) & (US$ Million)
Table 54. Latin America Myocardial Fibrosis Market Size by Type (2016-2021) (US$ Million)
Table 55. Latin America Myocardial Fibrosis Market Size by Type (2022-2027) & (US$ Million)
Table 56. Latin America Myocardial Fibrosis Market Size by Application (2016-2021) (US$ Million)
Table 57. Latin America Myocardial Fibrosis Market Size by Application (2022-2027) & (US$ Million)
Table 58. Latin America Myocardial Fibrosis Market Size by Country (2016-2021) & (US$ Million)
Table 59. Latin America Myocardial Fibrosis Market Size by Country (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Myocardial Fibrosis Market Size by Type (2016-2021) (US$ Million)
Table 61. Middle East & Africa Myocardial Fibrosis Market Size by Type (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Myocardial Fibrosis Market Size by Application (2016-2021) (US$ Million)
Table 63. Middle East & Africa Myocardial Fibrosis Market Size by Application (2022-2027) & (US$ Million)
Table 64. Middle East & Africa Myocardial Fibrosis Market Size by Country (2016-2021) & (US$ Million)
Table 65. Middle East & Africa Myocardial Fibrosis Market Size by Country (2022-2027) & (US$ Million)
Table 66. Merck Company Details
Table 67. Merck Business Overview
Table 68. Merck Myocardial Fibrosis Product
Table 69. Merck Revenue in Myocardial Fibrosis Business (2016-2021) & (US$ Million)
Table 70. Merck Recent Development
Table 71. Evotec AG Company Details
Table 72. Evotec AG Business Overview
Table 73. Evotec AG Myocardial Fibrosis Product
Table 74. Evotec AG Revenue in Myocardial Fibrosis Business (2016-2021) & (US$ Million)
Table 75. Evotec AG Recent Development
Table 76. Miragen Therapeutics Company Details
Table 77. Miragen Therapeutics Business Overview
Table 78. Miragen Therapeutics Myocardial Fibrosis Product
Table 79. Miragen Therapeutics Revenue in Myocardial Fibrosis Business (2016-2021) & (US$ Million)
Table 80. Miragen Therapeutics Recent Development
Table 81. TRACON Pharmaceuticals Company Details
Table 82. TRACON Pharmaceuticals Business Overview
Table 83. TRACON Pharmaceuticals Myocardial Fibrosis Product
Table 84. TRACON Pharmaceuticals Revenue in Myocardial Fibrosis Business (2016-2021) & (US$ Million)
Table 85. TRACON Pharmaceuticals Recent Development
Table 86. Daewoong Pharmaceutical Company Details
Table 87. Daewoong Pharmaceutical Business Overview
Table 88. Daewoong Pharmaceutical Myocardial Fibrosis Product
Table 89. Daewoong Pharmaceutical Revenue in Myocardial Fibrosis Business (2016-2021) & (US$ Million)
Table 90. Daewoong Pharmaceutical Recent Development
Table 91. Galectin Therapeutics Company Details
Table 92. Galectin Therapeutics Business Overview
Table 93. Galectin Therapeutics Myocardial Fibrosis Product
Table 94. Galectin Therapeutics Revenue in Myocardial Fibrosis Business (2016-2021) & (US$ Million)
Table 95. Galectin Therapeutics Recent Development
Table 96. GTx Company Details
Table 97. GTx Business Overview
Table 98. GTx Myocardial Fibrosis Product
Table 99. GTx Revenue in Myocardial Fibrosis Business (2016-2021) & (US$ Million)
Table 100. GTx Recent Development
Table 101. Invivosciences Company Details
Table 102. Invivosciences Business Overview
Table 103. Invivosciences Revenue in Myocardial Fibrosis Business (2016-2021) & (US$ Million)
Table 104. Invivosciences Recent Development
Table 105. Lead Discovery Center Company Details
Table 106. Lead Discovery Center Business Overview
Table 107. Lead Discovery Center Myocardial Fibrosis Product
Table 108. Lead Discovery Center Revenue in Myocardial Fibrosis Business (2016-2021) & (US$ Million)
Table 109. Lead Discovery Center Recent Development
Table 110. MandalMed Company Details
Table 111. MandalMed Business Overview
Table 112. MandalMed Myocardial Fibrosis Product
Table 113. MandalMed Revenue in Myocardial Fibrosis Business (2016-2021) & (US$ Million)
Table 114. MandalMed Recent Development
Table 115. Research Programs/Design for This Report
Table 116. Key Data Information from Secondary Sources
Table 117. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Myocardial Fibrosis Market Share by Type: 2020 VS 2027
Figure 2. Small Molecule Therapeutic Modality Features
Figure 3. Protein Therapeutic Modality Features
Figure 4. Peptide Therapeutic Modality Features
Figure 5. Endoglin Antibody Therapeutic Modality Features
Figure 6. Stem Cell Therapeutic Modality Features
Figure 7. RNA Therapeutic Modality Features
Figure 8. Other Features
Figure 9. Global Myocardial Fibrosis Market Share by Application: 2020 VS 2027
Figure 10. Hospital Case Studies
Figure 11. Clinics Case Studies
Figure 12. Research Laboratories Case Studies
Figure 13. Myocardial Fibrosis Report Years Considered
Figure 14. Global Myocardial Fibrosis Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 15. Global Myocardial Fibrosis Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 16. Global Myocardial Fibrosis Market Share by Regions: 2020 VS 2027
Figure 17. Global Myocardial Fibrosis Market Share by Regions (2022-2027)
Figure 18. Global Myocardial Fibrosis Market Share by Players in 2020
Figure 19. Global Top Myocardial Fibrosis Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Myocardial Fibrosis as of 2020
Figure 20. The Top 10 and 5 Players Market Share by Myocardial Fibrosis Revenue in 2020
Figure 21. Global Myocardial Fibrosis Revenue Market Share by Type (2016-2021)
Figure 22. Global Myocardial Fibrosis Revenue Market Share by Type (2022-2027)
Figure 23. North America Myocardial Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. North America Myocardial Fibrosis Market Share by Type (2016-2027)
Figure 25. North America Myocardial Fibrosis Market Share by Application (2016-2027)
Figure 26. North America Myocardial Fibrosis Market Share by Country (2016-2027)
Figure 27. United States Myocardial Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Canada Myocardial Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe Myocardial Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Europe Myocardial Fibrosis Market Share by Type (2016-2027)
Figure 31. Europe Myocardial Fibrosis Market Share by Application (2016-2027)
Figure 32. Europe Myocardial Fibrosis Market Share by Country (2016-2027)
Figure 33. Germany Myocardial Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. France Myocardial Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. U.K. Myocardial Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Italy Myocardial Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Russia Myocardial Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Nordic Myocardial Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific Myocardial Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Asia-Pacific Myocardial Fibrosis Market Share by Type (2016-2027)
Figure 41. Asia-Pacific Myocardial Fibrosis Market Share by Application (2016-2027)
Figure 42. Asia-Pacific Myocardial Fibrosis Market Share by Region (2016-2027)
Figure 43. China Myocardial Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Japan Myocardial Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. South Korea Myocardial Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Southeast Asia Myocardial Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. India Myocardial Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Australia Myocardial Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America Myocardial Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Latin America Myocardial Fibrosis Market Share by Type (2016-2027)
Figure 51. Latin America Myocardial Fibrosis Market Share by Application (2016-2027)
Figure 52. Latin America Myocardial Fibrosis Market Share by Country (2016-2027)
Figure 53. Mexico Myocardial Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Brazil Myocardial Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa Myocardial Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Middle East & Africa Myocardial Fibrosis Market Share by Type (2016-2027)
Figure 57. Middle East & Africa Myocardial Fibrosis Market Share by Application (2016-2027)
Figure 58. Middle East & Africa Myocardial Fibrosis Market Share by Country (2016-2027)
Figure 59. Turkey Myocardial Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Saudi Arabia Myocardial Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. UAE Myocardial Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 62. Merck Revenue Growth Rate in Myocardial Fibrosis Business (2016-2021)
Figure 63. Evotec AG Revenue Growth Rate in Myocardial Fibrosis Business (2016-2021)
Figure 64. Miragen Therapeutics Revenue Growth Rate in Myocardial Fibrosis Business (2016-2021)
Figure 65. TRACON Pharmaceuticals Revenue Growth Rate in Myocardial Fibrosis Business (2016-2021)
Figure 66. Daewoong Pharmaceutical Revenue Growth Rate in Myocardial Fibrosis Business (2016-2021)
Figure 67. Galectin Therapeutics Revenue Growth Rate in Myocardial Fibrosis Business (2016-2021)
Figure 68. GTx Revenue Growth Rate in Myocardial Fibrosis Business (2016-2021)
Figure 69. Invivosciences Revenue Growth Rate in Myocardial Fibrosis Business (2016-2021)
Figure 70. Lead Discovery Center Revenue Growth Rate in Myocardial Fibrosis Business (2016-2021)
Figure 71. MandalMed Revenue Growth Rate in Myocardial Fibrosis Business (2016-2021)
Figure 72. Bottom-up and Top-down Approaches for This Report
Figure 73. Data Triangulation
Figure 74. Key Executives Interviewed

---